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Introduction: Medial arterial calciﬁcation is common in chronic kidney disease (CKD) and portends poor
clinical outcomes, but its progression relative to the severity of CKD and the role of other risk factors is
unknown because of the lack of reliable quantiﬁcation.
Methods: Calciﬁcation of breast arteries detected by mammography, which is exclusively medial and
correlates with medial calciﬁcation in peripheral arteries and with cardiovascular outcomes, was used to
measure the progression of medial arterial calciﬁcation in women with CKD and end-stage renal disease
(ESRD). Measurements showed intra- and interobserver correlations of 0.98, an interstudy variability of 8%
to 11%, and a correlation with computed tomographic measurements of 0.92.
Results: Progression of calciﬁcation was measured in 60 control subjects (estimated glomerular ﬁltration
rate (eGFR) $ 90 ml/min per 1.73 m2) and 137 subjects with CKD (eGFR < 90 ml/min per 1.73 m2). Pro-
gression in control subjects was linear over time and independent of age. The rate of progression was
increased in CKD but only at eGFR < 40 ml/min per 1.73 m2 (median, 8.1 vs. 3.9 mm/breast/yr in controls;
P ¼ 0.006). Progression accelerated markedly in subjects with ESRD (median, 20 mm/breast/yr; n ¼ 36), but
did not differ from controls after kidney transplantation (n ¼ 25). Diabetes signiﬁcantly augmented
progression in subjects with CKD and ESRD but not in controls.
Conclusion: Mammography is a convenient and reliable method to measure the progression of medial
arterial calciﬁcation. Progression does not increase until advanced stages of CKD, accelerates markedly in
ESRD, and returns to control rates after kidney transplantation. Diabetes signiﬁcantly increases progres-
sion in CKD and ESRD.
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V ascular calciﬁcation is common in subjects withadvanced stages of CKD and predicts poor out-
comes. This calciﬁcation comprises 2 distinct forms:
atherosclerotic calciﬁcation within neointimal plaques
and medial calciﬁcation within the smooth muscle layer
that can occur in the absence of atherosclerosis and is
linked to altered bone and mineral metabolism.
Although atherosclerotic calciﬁcation is increased in
advanced kidney disease,1 it is the medial form that is
particularly prevalent2,3 and is a greater risk factor for
cardiovascular events or death.4,5 However, it is not
clear when the risk of medial calciﬁcation begins in
CKD and how this is affected by other risk factors. This
information could help clarify the relationship between
medial arterial calciﬁcation and altered bone and min-
eral metabolism in CKD and guide potential therapies.
The study of medial calciﬁcation in humans has been
hampered by the lack of speciﬁc imaging and precise
quantiﬁcation. Because clinical studies have focused
almost exclusively on coronary arteries, the aorta, or its
branches, in which both medial and atherosclerotic
calciﬁcation occur, speciﬁc information on medial arterial
calciﬁcation is not provided. Attempts to distinguish and
quantify medial calciﬁcation through radiologic patterns
or by examining peripheral arteries are problematic
because of poor speciﬁcity, the existence of atheroscle-
rosis in some peripheral arteries, the lack of validation,
and the semiquantitative nature of the measurements.6,7
Precise information on medial calciﬁcation can only
come from arterial beds devoid of atherosclerosis in
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which calciﬁcation can be imaged with high sensitivity.
Arterial calciﬁcation is easily detected on mammograms
and is exclusively medial8 because atherosclerosis does
not occur in breast arteries.8,9 This calciﬁcation corre-
lates with calciﬁcation in peripheral arteries in ESRD10
and with cardiovascular disease both in the general
population11–13 and in subjects with ESRD,14 indicating
that it is a marker of medial arterial calciﬁcation sys-
temically. We have previously shown that the preva-
lence of breast arterial calciﬁcation (BAC) is increased at
least by stage 4 CKD15 but prevalence data lack sensi-
tivity and could be inﬂuenced by the duration of CKD,
which is difﬁcult to quantify. The effect of CKD and
ESRD on medial calciﬁcation is best determined by
following its progression, and to this end, we have
developed and validated a measurement of medial
arterial calciﬁcation on routine mammograms that can be
used to quantify its progression in CKD and ESRD.
METHODS
Mammography
Arterial calciﬁcation was identiﬁed on standard digital
mammograms as linear densities along the walls of ar-
teries and is easily distinguished from other calciﬁca-
tions. Only arteries with involvement of both walls
were considered calciﬁed, and when there was any
uncertainty, the region was considered not to be
calciﬁed. The lengths of calciﬁed segments were
measured using standard clinical PACS software
(Centricity PACS Radiology RA1000 Workstation; GE
Healthcare, Barrington, IL) and then summed and
expressed in mm/breast (Figure 1). There was no cor-
relation between breast size, modeled as a hemi-
ellipsoid (p/6  height  the square of the width at
the base), and BAC score (r ¼ 0.09; n ¼ 43). Mea-
surements were performed by 3 investigators, all
blinded to the clinical information. The correlation
between repeat measurements on 18 images by the
same individual was 0.98, with a mean difference of 9.9
mm or 13%, and the correlation between measurements
on 23 images by 2 individuals was 0.98, with a mean
difference of 14 mm or 14% (Figure 2a and b). To
minimize variability in measuring progression, all
mammograms from the same patient were measured by
a single individual.
Breast Computed Tomography
Validation of the mammography measurements was
performed by computed tomography (CT) of single
breasts in 10 subjects with arterial calciﬁcation, 33 to
71 days after the mammogram. This was performed
using a dedicated Koning Breast CT system (Koning
Corporation, West Henrietta, NY). Breast CT is a
recently developed technique that results in high-
resolution (273-mm) 3-dimensional images with high
contrast. The images were subjected to an algorithm to
correct for cupping artifacts and then analyzed using
ImageJ software (National Institutes of Health,
Bethesda, MD) via simultaneous inspection of coronal
and sagittal planes. Regions of vascular calciﬁcation
were selected, and the density of each voxel was
measured. The number of voxels with a density greater
than that of noncalciﬁed arteries was determined for
each region and these were then summed to give the
total number of calciﬁed voxels in the breast (volume
score). Validation of the CT quantiﬁcation of calcium
was performed by scanning a breast phantom consist-
ing of a cylindrical plastic container of shortening
(adipose tissue equivalent) embedded with small tubes
containing suspensions of varying concentrations of
hydroxyapatite in shortening. The mean Hounsﬁeld
units in each standard and the background surround-
ing each standard were measured, and the difference
yielded a linear relationship between Hounsﬁeld units
and calcium density (r2 ¼ 0.994; Supplementary
Figure S1). The slope was applied to the density of
each calciﬁed voxel (above baseline) and multiplied by
voxel volume (0.02 ml) to determine the total amount of
arterial calcium. The correlation between the CT vol-
ume and BAC measured on craniocaudal views was 0.92
(Figure 2c) as compared with 0.85 for BAC measured on
mediolateral oblique views (not shown). Correlation
with the total amount of calcium was not as strong
(0.86), which is consistent with the fact that the length
rather than the density of calciﬁcations was measured
Figure 1. Arterial calciﬁcation and its measurement on a portion of a
mammogram.
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on mammograms. Applying a semiquantitative
weighting of severity to the mammography measure-
ments did not improve this correlation, indicating that
assessment of the density of calciﬁcation on mammo-
grams is unreliable. Because of the stronger correlation
with CT scans, craniocaudal views were used for all
subsequent measurements.
Subjects
Subjects with and without CKD were identiﬁed from a
computerized search of medical records at Emory
Healthcare, for all mammograms scheduled between
January 3, 2011, and December 17, 2013. Additional
information that was obtained included date of birth,
sex, race, history of diabetes or diabetes medications,
history of warfarin use, serum creatinine levels, and
dates of measurement. Men and subjects with current
warfarin use, which is associated with medial arterial
calciﬁcation,16 were excluded. The glomerular ﬁltration
rate was estimated (eGFR) in ml/min per 1.73 m2 as
determined by the 4-variable equation from the Modi-
ﬁcation of Diet in Renal Disease Study.17 All available
subjects with eGFR < 30 ml/min per 1.73 m2 were
screened, whereas subjects with eGFR $ 30 ml/min per
1.73 m2 were randomly selected for screening by birth
month. The cohort was supplemented with diabetic
women with eGFR $ 60 ml/min per 1.73 m2, again
selected at random, to account for the higher prevalence
of diabetes in subjects with lower eGFR. Women with
BAC and at least 1 subsequent mammogram underwent
medical record review to conﬁrm the CKD stage during
the mammogram interval and to exclude subjects who
were receiving warfarin or who had ESRD or underwent
kidney transplantation. The eGFR assigned to each
subject was calculated from the estimated serum creat-
inine value at the midpoint between the 2 mammograms,
which was determined by interpolation of values ob-
tained before and after mammograms on the basis of a
linear increase in serum creatinine level over time.
Women who had ESRD or underwent kidney trans-
plantation and mammograms were identiﬁed by
comparing the aforementionedmammogram search with
searches for all subjects with either diagnosis. ESRDwas
identiﬁed by chronic outpatient hemodialysis during
the mammogram interval, and only subjects with serum
creatinine levels < 1.8 mg/dl (159 umol/l) after kidney
transplantation during the mammogram interval were
included. Conﬁrmation of diabetes, warfarin use, onset
of ESRD, dialysis modality, and transplantation were all
obtained through physician review of medical records.
Diabetes was identiﬁed as a diagnosis of diabetes in the
medical record and the use of hypoglycemic medications
during the mammogram interval. All protocols were
approved by the Institutional Review Board of Emory
University.
Statistics
The distribution of data was assessed for normality
using the Shapiro-Wilk test. Normally distributed
continuous variables are presented as mean  SE and
analyzed using the Student t test. Nonparametric data
are presented as median and interquartile range and
analyzed using the Mann-Whitney U test or Kruskal-
Wallis test. Binary variables were analyzed using the
Fisher exact test. Progression of BAC is presented as
Figure 2. Reproducibility and accuracy of the measurement of
breast arterial calciﬁcation (BAC) on mammograms. (a) Two blinded
measurements on the same image by the same individual. (b)
Measurements on the same image by 2 individuals. (c) Correlation
between BAC measured by mammography and the volume of
calciﬁed arteries measured by computed tomography.
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Tukey box plots, in which the median is shown within
boxes representing the interquartile range and error
bars indicating maximum and minimum data points
within 1.5 times the interquartile range above and
below the quartiles. Data points outside this range are
depicted individually.
RESULTS
The time course of BAC progression was examined in
11 subjects with at least 5 sequential mammograms. To
minimize variability due to biological factors, only
subjects without diabetes, warfarin use, or renal failure
(eGFR > 90 ml/min per 1.73 m2) were included. Pro-
gression was analyzed by linear regression in each
subject (examples shown in Supplementary Figure S2).
The mean correlation coefﬁcient for the group was
0.79, and the mean of the residuals of this regression
did not differ signiﬁcantly from zero, which is
consistent with a linear progression. These data were
also used to estimate interstudy variability, which in-
cludes variability in the imaging and variability in the
measurement. The absolute values of the residuals of
this regression, representing the differences between
measured and expected BAC, averaged over the entire
cohort, yielded a mean error of 7.24  1.01 mm/breast
or 11.1%  1.4%. The percent error is magniﬁed by
minimal BAC in some subjects. When calculated
instead by dividing the error by the mean BAC score
for the entire group (94.5 mm/breast), the error was
7.7%. These data were also used to determine the error
associated with measuring the rate of BAC on just
2 mammograms instead of 5. This was dependent on
the interval between mammograms, with an error of
w2 mm/breast/yr for intervals of $3 years
(Supplementary Figure S3). Therefore, an interval of at
least 3 years was used to measure progression of BAC,
with intervals of <3 years used only when other
mammograms were not available.
Progression of BAC was measured in 60 women
without CKD (eGFR $ 90 ml/min per 1.73 m2) and 137
women with CKD (eGFR < 90 ml/min per 1.73 m2). The
latter cohort was divided into tertiles on the basis of
eGFR, and the characteristics of subjects in these tertiles
and control subjects are listed in Table 1. Neither the
values for BAC nor the progression rate was normally
distributed, and these values are presented as medians
and interquartile ranges. There were no differences in
age, race, prevalence of diabetes, or baseline BAC be-
tween the groups. The mammogram interval was greater
in women without CKD, but was similar in each of the
CKD tertiles. The progression rate was the same in the
ﬁrst 2 tertiles as in controls but signiﬁcantly higher in
the lowest tertile of eGFR. The individual data points for
subjects with CKD are shown in Figure 3 along with the
interquartile range in the control cohort.
An additional 36 subjects with ESRD and 25 subjects
with kidney transplants were studied, and their char-
acteristics are listed in Table 2. Age, race, prevalence of
diabetes, and baseline BAC did not differ signiﬁcantly
between the groups. The proportion of African
Americans was higher in both these groups compared
with controls and subjects with CKD, but race did not
signiﬁcantly affect BAC progression in a multivariable
analysis of controls and subjects with CKD. The
mammogram interval was shorter in subjects with
ESRD. Although this could increase the error in
determining the rate of progression, this is compen-
sated by the much higher rate of progression. The
progression of BAC is shown graphically and compared
with that in controls and the third CKD tertile in
Figure 4. Subjects with ESRD had a signiﬁcantly higher
rate of progression than did subjects in the third CKD
tertile, whereas subjects with kidney transplants had a
signiﬁcantly lower progression rate than did subjects
Table 1. Characteristics of subjects with CKD and controls
Characteristic No CKD CKD tertile 1 CKD tertile 2 CKD tertile 3
n 60 45 46 46
Age (yr) 77.0  1.0 74.4  1.2 78.3  1.0 73.4  1.5
Diabetes (%) 28 33 26 33
Race: African
American (%)
30 38 20 46
eGFR (ml/min
per 1.73 m2)a
90–170 53–90 40–52 6–39
BAC0 (mm/breast) 26 (12–71) 22 (12–54) 33 (13–79) 31 (14–95)
MG interval (yr) 4.1  0.3 2.5  0.1 2.7  0.2 2.5  0.2
BAC rate (mm/breast/yr) 3.9 (0.7–8.0) 3.3 (0.3–6.2) 4.2 (0.3–10) 8.1 (2.4–23)b
Data are expressed as mean  SE, or median (interquartile range).
BAC, breast arterial calciﬁcation; BAC0, baseline breast arterial calcification; CKD,
chronic kidney disease; eGFR, estimated glomerular filtration rate; MG, mammogram.
aeGFR is presented as a range.
bP ¼ 0.006 by the Kruskal-Wallis test.
Figure 3. Progression of breast arterial calciﬁcation in subjects with
chronic kidney disease. The dashed lines indicate the ﬁrst and third
quartiles of progression in control subjects. eGFR, estimated
glomerular ﬁltration rate.
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with ESRD, which was not different from the rate in
subjects without CKD. The rate was negative in 40% of
the subjects with kidney transplants. The effect of
diabetes on progression of BAC was examined in con-
trols, subjects with CKD, and subjects with ESRD
(Figure 5). Among control subjects, progression was
identical in diabetics and nondiabetics, but diabetes
was associated with a signiﬁcantly higher rate of pro-
gression in subjects with CKD (2-fold in median rate)
and subjects with ESRD (4.4-fold in median rate).
DISCUSSION
This is the ﬁrst quantitative measurement of medial
arterial calciﬁcation and its progression in humans. The
measurements correlated well with measurements
obtained by CT, and the reproducibility and sensitivity
were sufﬁcient to detect the normal progression of
calciﬁcation. Although limited to breast arteries,
abundant data demonstrate that this calciﬁcation is
indicative of medial calciﬁcation elsewhere. There is a
strong correlation with cardiovascular disease both in
the general population11–13 and in subjects with
ESRD,14 as well as with medial calciﬁcation in periph-
eral arteries in subjects with ESRD10 and other subjects
(K. H. Han and W. C. O’Neill, unpublished data).
Furthermore, warfarin increases calciﬁcation in both
breast arteries16 and peripheral arteries.18 Although
measurements have been performed on radiographs of
distal extremities,7 where the calciﬁcation is primarily
medial,19,20 these are only semiquantitative and are
limited by their insensitivity, lack of validation, and
the fact that atherosclerotic calciﬁcation can occur at
these sites.20
Although CKD is known to be a risk factor for
medial arterial calciﬁcation,4,5 the stage at which this
risk begins has remained unknown. This is best
examined by measuring progression rather than
quantity, which can be inﬂuenced by the duration of
CKD and other risk factors. A signiﬁcant 2-fold
greater progression was seen in subjects with
eGFR < 40 ml/min per 1.73 m2 than in controls but not
in CKD subjects with higher eGFR, indicating that the
risk for medial arterial calciﬁcation begins in advanced
CKD. These results are consistent with our previous




Age (yr) 60.1  1.7 57.7  1.9
Diabetes (%) 44 28
Race: African American (%) 86 64
ESRD duration (yr)a 5.2  0.6 5.5  0.7
Serum creatinine level (mg/dl) 1.09  0.1
BAC0 (mm/breast) 43 (10 to 97) 49 (6 to 106)
MG interval (yr) 2.1  0.2 2.8  0.3
BAC rate (mm/breast/yr) 20 (7.4 to 51) 0.5 (0.5 to 5.2)
Data are expressed as mean  SE, or median (interquartile range).
BAC, breast arterial calciﬁcation; BAC0, baseline breast arterial calcification; ESRD,
end-stage renal disease; MG, mammogram.
aESRD duration denotes years of renal replacement therapy before the most recent
mammogram or before kidney transplantation.
Figure 4. Progression of breast arterial calciﬁcation in subjects with
end-stage renal disease (ESRD) or subjects who underwent kidney
transplantation. The boxes represent the interquartile range (IQR),
with the intervening line indicating the median. The error bars
indicate the maximum and minimum data points within 1.5 the IQR
of the ﬁrst and third quartiles, with symbols indicating outlying
points. Data for control subjects and subjects in the lowest chronic
kidney disease tertile from Figure 2 are shown for comparison.
Significances are determined using the Mann-Whitney U test. eGFR,
estimated glomerular filtration rate.
Figure 5. Progression of breast arterial calciﬁcation in subjects with
and without diabetes. The boxes represent the interquartile range
(IQR), with the intervening line indicating the median. The error bars
indicate the maximum and minimum data points within 1.5 the IQR
of the ﬁrst and third quartiles, with symbols indicating outlying
points. Signiﬁcances are determined using the Mann-Whitney U
test. CKD, chronic kidney disease; eGFR, estimated glomerular
filtration rate; ESRD, end-stage renal disease.
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data showing an increase in the prevalence of BAC in
women with stage 4 or 5 CKD, but not CKD 3,15 as well
as with a recent study5 showing increased calciﬁcation
of hand arteries in stages 4 and 5 compared to stage 3.
However, the latter study did not examine earlier
stages. A histologic study of coronary arteries showed
medial calciﬁcation only in subjects with stage 4 CKD
or higher1 but the numbers were small and other risk
factors were not controlled.
Progression of BAC accelerated markedly in subjects
undergoing hemodialysis. This could be due to poorer
residual renal function or some aspect of hemodialysis
or ESRD care, but it is clear that hemodialysis does not
improve the risk. The progression rate in subjects with
transplanted kidneys did not differ from that in control
subjects. Although this could represent bias in select-
ing healthier subjects for transplantation, there was no
difference in age, diabetes prevalence, ESRD duration,
or baseline calciﬁcation between subjects with ESRD
and subjects with transplanted kidneys, suggesting
that progression returns to control levels after kidney
transplantation and that the risk of calciﬁcation is
eliminated by restoring renal function. The fact that
the rate was negative in 40% of the subjects with
transplanted kidneys compared with 17% of controls
raises the possibility of reversal of calciﬁcation after
transplantation.
Progression of calciﬁcation was strongly inﬂuenced
by the presence of diabetes, which signiﬁcantly
increased the rate in subjects with CKD progression or
ESRD. Interestingly, diabetes did not increase in con-
trol subjects, indicating an important interaction be-
tween diabetes and CKD. Although diabetes has been
associated with increased BAC21,22 and medial arterial
calciﬁcation elsewhere,23 renal function was rarely
evaluated and it is possible that some of these subjects
had advanced CKD. Interestingly, age, which is a
potent determinant of the prevalence of BAC,24 had no
effect on progression in controls or subjects with CKD.
This suggests that the effect of age on prevalence is due
to a steady rate of accumulation over time.
The progression of medial arterial calciﬁcation in
relation to eGFR may provide some insight into its
linkage with altered bone and mineral metabolism,
which has been ascribed to a number of factors
including hyperphosphatemia, hyperparathyroidism,
and elevated ﬁbroblast growth factor 23 levels. The fact
that progression of medial arterial calciﬁcation in-
creases only in advanced CKD is not consistent with a
major role for parathyroid hormone or ﬁbroblast
growth factor 23, levels of which increase at earlier
stages.25,26 However, the data are consistent with a role
for hyperphosphatemia, which begins to develop at
eGFR < 40 ml/min per 1.73 m2.25 Reliable data on
mineral metabolism were not available in this retro-
spective study, and a prospective study will be
required to address this. Calciﬁcation accelerated
markedly in subjects undergoing hemodialysis.
Although this could be due to further loss of renal
function, other factors such as postdialysis alkalemia or
the more frequent use of active vitamin D compounds
may play a role. It is also possible that subjects with
more rapid calciﬁcation may be more likely to progress
to ESRD.
A major limitation of this study is that the measure-
ment of medial arterial calciﬁcation is restricted to fe-
males. The breast is uniquely suited for the detection
and measurement of medial arterial calciﬁcation because
of the sensitivity of mammography and the periarterial
fat, and a vascular bed of comparable ease and sensitivity
of imaging does not exist in men. However, insights
obtained in women are likely to be applicable to men as
well. For instance, the increased prevalence of BAC in
warfarin users16 was subsequently noted in the lower
limb radiographs in men.18 Another limitation is the
reduced frequency of mammography in women with
advanced CKD, which is likely explained by current
data and recommendations on the beneﬁts versus limited
life expectancy in this population.27–29 Because
screening mammography is recommended only in
womenwith a life expectancy of>5 years, the cohorts in
this study likely represent the healthiest of these sub-
jects and the results may therefore underestimate the
true rates of calciﬁcation in advanced CKD. Given the
correlation between clinical outcomes and medial arte-
rial calciﬁcation in the breast and other locations in CKD
and ESRD,4,5,14 mammography may have a useful clin-
ical role beyond screening for cancer.
In summary, BAC can be easily and reliably quan-
tiﬁed and followed by routine mammography and can
deﬁne the risk of medial arterial calciﬁcation in CKD
and ESRD. Because screening mammography within an
age range applicable to cardiovascular disease has been
routine for many years, a large body of retrospective
data is available for analysis. The availability of serial
mammograms also allows longitudinal studies to be
performed in retrospective cohorts. In contrast to other
protocols for quantifying vascular calciﬁcation,
mammography is clinically indicated in most women
within the relevant age range, and prospective studies
can be performed with little or no additional imaging
cost or radiation exposure.
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SUPPLEMENTARY MATERIAL
Figure S1. Validation of the measurement of calcium by
breast computed tomography. Relationship between
Hounsﬁeld units (HU) and the density of hydroyapatite
(HA) in a breast phantom.
Figure S2. Time course of breast arterial calciﬁcation in 5
subjects. Data are the total for both breasts. Each graph
represents a different subject, and the linear regression
line is shown for each.
Figure S3. Error in themeasurement of progression of breast
arterial calciﬁcation obtained from 2 mammograms as a
function of the interval between mammograms. The
ordinate is the absolute difference between the rate
calculated from 2 mammograms and the rate calculated by
linear regression of measurements from 5 mammograms.
The numbers above the bars indicate the number of subjects.
Supplementary material is linked to the online version of
the paper at www.kireports.org.
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